Date:2/25/2009

ment, net 355,479 542,679 Other assets 156,788 280,317 Total assets $6,861,024 $8,181,016 Liabilities and Stockholders' Equity Current liabilities Accounts payable and accrued expenses $659,009 $626,693 Accrued payroll 554,425 221,013 Unearned revenue 291,594 279,275 Total current liabilities 1,505,028 1,126,981 Commitments and Contingencies Stockholders' Equity Convertible preferred stock, $0.001 par value; 15,000,000 shares authorized; 8,400 shares designated Series A; issued and outstanding: 3,976 at December 31, 2008, 4,001 at December 31, 2007; liquidation preference $1,000 per share 4 4 6,000 shares designated Series B; issued and outstanding: 4,226 at December 31, 2008, 4,230 at December 31, 2007; liquidation preference $1,000 per share 4 4 Common Stock, $0.001 par value; 85,000,000 shares authorized; shares issued and outstanding: 23,502,352 at December 31, 2008, 23,225,664 at December 31, 2007 23,503 23,226 Additional paid-in capital 16,546,550 15,715,557 Accumulated deficit (11,214,065) (8,684,756) Total stockholders' equity 5,355,996 7,054,035 Total liabilities and stockholders' equity $6,861,024 $8,181,016

    CONTACT:  Company Contact:
              Molly Henderson
              Chief Business and Financial Officer
              500 Linden Oaks
              Rochester, New
'/>"/>
SOURCE  VirtualScopics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 
Related biology technology :

1. Nasdaq Grants VirtualScopics Request for Continued Listing
2. VirtualScopics Schedules Fourth Quarter 2008 Earnings Announcement
3. Pharsight Achieves First License Sale for Public-Source Database
4. GenoLogics Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform
5. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
6. Signalife Achieves $1.98 Million Sales Orders Thus Far
7. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
8. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
9. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
10. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
11. NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria